ABSTRACT

Introduction: Atopic dermatitis (AD) is a heterogeneous, chronic, inflammatory skin disease with a non-negligible prevalence at present. Its pathogenesis is complex, but mainly characterized by constitutive T helper type 2 (Th2)-cell activation. Systemic therapies for moderate-to-severe AD can be associated with adverse events that encumber their satisfactory long-term use. Several drugs targeting relevant molecules in the immunopathogenesis of AD have been approved or are under clinical development for the treatment of moderate to severe AD. To elaborate this review, literature searches were performed in PubMed on 29 August 2020.

Areas covered: This narrative literature review is focused on the pivotal role of IL-13 in the immunopathogenesis of AD and other skin diseases.

Expert opinion: Dupilumab has demonstrated the central role of IL-13 and IL-4 in the pathogenesis of AD, asthma, and other diseases in the atopic spectrum. In addition, phase III randomized clinical trials (RCTs) evaluating specific blockade of IL-13 with tralokinumab for treatment of AD also demonstrated favorable results, and phase III RCT evaluating lebrikizumab are ongoing. The role of IL-13 in other skin diseases should be further investigated.

摘要

简介：特应性皮炎（AD）是一种异质性、慢性、炎症性皮肤病，目前其患病率不容忽视。其发病机制复杂，但主要特征是组成型 2 型辅助性 T 细胞 (Th2) 细胞活化。中度至重度 AD 的全身治疗可能与阻碍其长期令人满意的使用的不良事件相关。几种靶向 AD 免疫发病机制中相关分子的药物已被批准或正在临床开发中，用于治疗中度至重度 AD。为了详细说明本综述，于 2020 年 8 月 29 日在 PubMed 中进行了文献检索。

涵盖的领域：这篇叙述性文献综述的重点是 IL-13 在 AD 和其他皮肤病的免疫发病机制中的关键作用。

专家意见： Dupilumab 已经证明了 IL-13 和 IL-4 在 AD、哮喘和其他特应性谱系疾病的发病机制中的核心作用。此外，评估 tralokinumab 对 IL-13 特异性阻断治疗 AD 的 III 期随机临床试验 (RCT) 也显示出良好的结果，评估 lebrikizumab 的 III 期 RCT 正在进行中。应进一步研究 IL-13 在其他皮肤病中的作用。